author_facet Jinjuvadia, Raxitkumar
Njei, Basile M.
Ditah, Ivo C.
Jinjuvadia, Raxitkumar
Njei, Basile M.
Ditah, Ivo C.
author Jinjuvadia, Raxitkumar
Njei, Basile M.
Ditah, Ivo C.
spellingShingle Jinjuvadia, Raxitkumar
Njei, Basile M.
Ditah, Ivo C.
Journal of Clinical Oncology
The association between metabolic syndrome and primary liver cancer: A meta-analysis.
Cancer Research
Oncology
author_sort jinjuvadia, raxitkumar
spelling Jinjuvadia, Raxitkumar Njei, Basile M. Ditah, Ivo C. 0732-183X 1527-7755 American Society of Clinical Oncology (ASCO) Cancer Research Oncology http://dx.doi.org/10.1200/jco.2012.30.4_suppl.175 <jats:p> 175 </jats:p><jats:p> Background: The Metabolic syndrome (MetS) and/or its individual components have been liked to the development of cancer. Recent studies have suggested a similar link to Primary Liver Cancer (PLC). The mechanism for the development of cancer in this group of patients remains unclear. The aim of this study was to evaluate the direction and magnitude of the association between the MetS and PLC. </jats:p><jats:p> Methods: Two reviewers independently conducted a systemic search of the PubMed, OvidSP and Cochrane Library databases from January 1980 to July 2011. Search terms included ‘Metabolic syndrome’, ‘insulin resistance syndrome’ combined with ‘hepatocellular carcinoma’, ‘liver cancer’ and ‘GI malignancy’. No language restriction was applied to the search. Only studies reporting an effect measure for the association between MetS and PLC were eligible for inclusion. Metabolic syndrome was defined according to NCEP/ATP III, IDF, AHA and WHO guidelines. Identified articles were reviewed for additional references. Combined analysis including all studies was done using a random effects model. Publication bias was assessed using the Begg and Egger’s tests, with a visual inspection of funnel plot. All analyses were performed using Comprehensive Meta-Analysis version 2 software. </jats:p><jats:p> Results: Five studies (4 cohort and 1 case-control) including 863,714 participants were included in the analysis. The age range of participants was between 20 and 88 years. The combined analysis showed an overall 74% increase risk of PLC in cases with MetS (RR: 1.74, 95% CI: 1.36-2.24). After excluding the single case-control study from analysis, the overall risk ratio remained statistically significant (RR: 1.62, 95% CI: 1.22-2.15). Funnel plot inspection, Begg and Egger’s tests showed no evidence of publication bias, whether in the combined or subgroup analysis. </jats:p><jats:p> Conclusions: Though studies are scarce, currently available epidemiologic data is suggestive of positive association with significantly higher risk of liver cancer among patients with metabolic syndrome. More studies are required before reaching conclusive statement regarding this association. Further better-designed studies with good quality data with definitely aid in strengthening this association. </jats:p> The association between metabolic syndrome and primary liver cancer: A meta-analysis. Journal of Clinical Oncology
doi_str_mv 10.1200/jco.2012.30.4_suppl.175
facet_avail Online
Free
finc_class_facet Medizin
format ElectronicArticle
fullrecord blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTIwMC9qY28uMjAxMi4zMC40X3N1cHBsLjE3NQ
id ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTIwMC9qY28uMjAxMi4zMC40X3N1cHBsLjE3NQ
institution DE-Ch1
DE-L229
DE-D275
DE-Bn3
DE-Brt1
DE-Zwi2
DE-D161
DE-Gla1
DE-Zi4
DE-15
DE-Rs1
DE-Pl11
DE-105
DE-14
imprint American Society of Clinical Oncology (ASCO), 2012
imprint_str_mv American Society of Clinical Oncology (ASCO), 2012
issn 1527-7755
0732-183X
issn_str_mv 1527-7755
0732-183X
language English
mega_collection American Society of Clinical Oncology (ASCO) (CrossRef)
match_str jinjuvadia2012theassociationbetweenmetabolicsyndromeandprimarylivercancerametaanalysis
publishDateSort 2012
publisher American Society of Clinical Oncology (ASCO)
recordtype ai
record_format ai
series Journal of Clinical Oncology
source_id 49
title The association between metabolic syndrome and primary liver cancer: A meta-analysis.
title_unstemmed The association between metabolic syndrome and primary liver cancer: A meta-analysis.
title_full The association between metabolic syndrome and primary liver cancer: A meta-analysis.
title_fullStr The association between metabolic syndrome and primary liver cancer: A meta-analysis.
title_full_unstemmed The association between metabolic syndrome and primary liver cancer: A meta-analysis.
title_short The association between metabolic syndrome and primary liver cancer: A meta-analysis.
title_sort the association between metabolic syndrome and primary liver cancer: a meta-analysis.
topic Cancer Research
Oncology
url http://dx.doi.org/10.1200/jco.2012.30.4_suppl.175
publishDate 2012
physical 175-175
description <jats:p> 175 </jats:p><jats:p> Background: The Metabolic syndrome (MetS) and/or its individual components have been liked to the development of cancer. Recent studies have suggested a similar link to Primary Liver Cancer (PLC). The mechanism for the development of cancer in this group of patients remains unclear. The aim of this study was to evaluate the direction and magnitude of the association between the MetS and PLC. </jats:p><jats:p> Methods: Two reviewers independently conducted a systemic search of the PubMed, OvidSP and Cochrane Library databases from January 1980 to July 2011. Search terms included ‘Metabolic syndrome’, ‘insulin resistance syndrome’ combined with ‘hepatocellular carcinoma’, ‘liver cancer’ and ‘GI malignancy’. No language restriction was applied to the search. Only studies reporting an effect measure for the association between MetS and PLC were eligible for inclusion. Metabolic syndrome was defined according to NCEP/ATP III, IDF, AHA and WHO guidelines. Identified articles were reviewed for additional references. Combined analysis including all studies was done using a random effects model. Publication bias was assessed using the Begg and Egger’s tests, with a visual inspection of funnel plot. All analyses were performed using Comprehensive Meta-Analysis version 2 software. </jats:p><jats:p> Results: Five studies (4 cohort and 1 case-control) including 863,714 participants were included in the analysis. The age range of participants was between 20 and 88 years. The combined analysis showed an overall 74% increase risk of PLC in cases with MetS (RR: 1.74, 95% CI: 1.36-2.24). After excluding the single case-control study from analysis, the overall risk ratio remained statistically significant (RR: 1.62, 95% CI: 1.22-2.15). Funnel plot inspection, Begg and Egger’s tests showed no evidence of publication bias, whether in the combined or subgroup analysis. </jats:p><jats:p> Conclusions: Though studies are scarce, currently available epidemiologic data is suggestive of positive association with significantly higher risk of liver cancer among patients with metabolic syndrome. More studies are required before reaching conclusive statement regarding this association. Further better-designed studies with good quality data with definitely aid in strengthening this association. </jats:p>
container_issue 4_suppl
container_start_page 175
container_title Journal of Clinical Oncology
container_volume 30
format_de105 Article, E-Article
format_de14 Article, E-Article
format_de15 Article, E-Article
format_de520 Article, E-Article
format_de540 Article, E-Article
format_dech1 Article, E-Article
format_ded117 Article, E-Article
format_degla1 E-Article
format_del152 Buch
format_del189 Article, E-Article
format_dezi4 Article
format_dezwi2 Article, E-Article
format_finc Article, E-Article
format_nrw Article, E-Article
_version_ 1792328209404002307
geogr_code not assigned
last_indexed 2024-03-01T12:49:38.122Z
geogr_code_person not assigned
openURL url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=The+association+between+metabolic+syndrome+and+primary+liver+cancer%3A+A+meta-analysis.&rft.date=2012-02-01&genre=article&issn=1527-7755&volume=30&issue=4_suppl&spage=175&epage=175&pages=175-175&jtitle=Journal+of+Clinical+Oncology&atitle=The+association+between+metabolic+syndrome+and+primary+liver+cancer%3A+A+meta-analysis.&aulast=Ditah&aufirst=Ivo+C.&rft_id=info%3Adoi%2F10.1200%2Fjco.2012.30.4_suppl.175&rft.language%5B0%5D=eng
SOLR
_version_ 1792328209404002307
author Jinjuvadia, Raxitkumar, Njei, Basile M., Ditah, Ivo C.
author_facet Jinjuvadia, Raxitkumar, Njei, Basile M., Ditah, Ivo C., Jinjuvadia, Raxitkumar, Njei, Basile M., Ditah, Ivo C.
author_sort jinjuvadia, raxitkumar
container_issue 4_suppl
container_start_page 175
container_title Journal of Clinical Oncology
container_volume 30
description <jats:p> 175 </jats:p><jats:p> Background: The Metabolic syndrome (MetS) and/or its individual components have been liked to the development of cancer. Recent studies have suggested a similar link to Primary Liver Cancer (PLC). The mechanism for the development of cancer in this group of patients remains unclear. The aim of this study was to evaluate the direction and magnitude of the association between the MetS and PLC. </jats:p><jats:p> Methods: Two reviewers independently conducted a systemic search of the PubMed, OvidSP and Cochrane Library databases from January 1980 to July 2011. Search terms included ‘Metabolic syndrome’, ‘insulin resistance syndrome’ combined with ‘hepatocellular carcinoma’, ‘liver cancer’ and ‘GI malignancy’. No language restriction was applied to the search. Only studies reporting an effect measure for the association between MetS and PLC were eligible for inclusion. Metabolic syndrome was defined according to NCEP/ATP III, IDF, AHA and WHO guidelines. Identified articles were reviewed for additional references. Combined analysis including all studies was done using a random effects model. Publication bias was assessed using the Begg and Egger’s tests, with a visual inspection of funnel plot. All analyses were performed using Comprehensive Meta-Analysis version 2 software. </jats:p><jats:p> Results: Five studies (4 cohort and 1 case-control) including 863,714 participants were included in the analysis. The age range of participants was between 20 and 88 years. The combined analysis showed an overall 74% increase risk of PLC in cases with MetS (RR: 1.74, 95% CI: 1.36-2.24). After excluding the single case-control study from analysis, the overall risk ratio remained statistically significant (RR: 1.62, 95% CI: 1.22-2.15). Funnel plot inspection, Begg and Egger’s tests showed no evidence of publication bias, whether in the combined or subgroup analysis. </jats:p><jats:p> Conclusions: Though studies are scarce, currently available epidemiologic data is suggestive of positive association with significantly higher risk of liver cancer among patients with metabolic syndrome. More studies are required before reaching conclusive statement regarding this association. Further better-designed studies with good quality data with definitely aid in strengthening this association. </jats:p>
doi_str_mv 10.1200/jco.2012.30.4_suppl.175
facet_avail Online, Free
finc_class_facet Medizin
format ElectronicArticle
format_de105 Article, E-Article
format_de14 Article, E-Article
format_de15 Article, E-Article
format_de520 Article, E-Article
format_de540 Article, E-Article
format_dech1 Article, E-Article
format_ded117 Article, E-Article
format_degla1 E-Article
format_del152 Buch
format_del189 Article, E-Article
format_dezi4 Article
format_dezwi2 Article, E-Article
format_finc Article, E-Article
format_nrw Article, E-Article
geogr_code not assigned
geogr_code_person not assigned
id ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTIwMC9qY28uMjAxMi4zMC40X3N1cHBsLjE3NQ
imprint American Society of Clinical Oncology (ASCO), 2012
imprint_str_mv American Society of Clinical Oncology (ASCO), 2012
institution DE-Ch1, DE-L229, DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161, DE-Gla1, DE-Zi4, DE-15, DE-Rs1, DE-Pl11, DE-105, DE-14
issn 1527-7755, 0732-183X
issn_str_mv 1527-7755, 0732-183X
language English
last_indexed 2024-03-01T12:49:38.122Z
match_str jinjuvadia2012theassociationbetweenmetabolicsyndromeandprimarylivercancerametaanalysis
mega_collection American Society of Clinical Oncology (ASCO) (CrossRef)
physical 175-175
publishDate 2012
publishDateSort 2012
publisher American Society of Clinical Oncology (ASCO)
record_format ai
recordtype ai
series Journal of Clinical Oncology
source_id 49
spelling Jinjuvadia, Raxitkumar Njei, Basile M. Ditah, Ivo C. 0732-183X 1527-7755 American Society of Clinical Oncology (ASCO) Cancer Research Oncology http://dx.doi.org/10.1200/jco.2012.30.4_suppl.175 <jats:p> 175 </jats:p><jats:p> Background: The Metabolic syndrome (MetS) and/or its individual components have been liked to the development of cancer. Recent studies have suggested a similar link to Primary Liver Cancer (PLC). The mechanism for the development of cancer in this group of patients remains unclear. The aim of this study was to evaluate the direction and magnitude of the association between the MetS and PLC. </jats:p><jats:p> Methods: Two reviewers independently conducted a systemic search of the PubMed, OvidSP and Cochrane Library databases from January 1980 to July 2011. Search terms included ‘Metabolic syndrome’, ‘insulin resistance syndrome’ combined with ‘hepatocellular carcinoma’, ‘liver cancer’ and ‘GI malignancy’. No language restriction was applied to the search. Only studies reporting an effect measure for the association between MetS and PLC were eligible for inclusion. Metabolic syndrome was defined according to NCEP/ATP III, IDF, AHA and WHO guidelines. Identified articles were reviewed for additional references. Combined analysis including all studies was done using a random effects model. Publication bias was assessed using the Begg and Egger’s tests, with a visual inspection of funnel plot. All analyses were performed using Comprehensive Meta-Analysis version 2 software. </jats:p><jats:p> Results: Five studies (4 cohort and 1 case-control) including 863,714 participants were included in the analysis. The age range of participants was between 20 and 88 years. The combined analysis showed an overall 74% increase risk of PLC in cases with MetS (RR: 1.74, 95% CI: 1.36-2.24). After excluding the single case-control study from analysis, the overall risk ratio remained statistically significant (RR: 1.62, 95% CI: 1.22-2.15). Funnel plot inspection, Begg and Egger’s tests showed no evidence of publication bias, whether in the combined or subgroup analysis. </jats:p><jats:p> Conclusions: Though studies are scarce, currently available epidemiologic data is suggestive of positive association with significantly higher risk of liver cancer among patients with metabolic syndrome. More studies are required before reaching conclusive statement regarding this association. Further better-designed studies with good quality data with definitely aid in strengthening this association. </jats:p> The association between metabolic syndrome and primary liver cancer: A meta-analysis. Journal of Clinical Oncology
spellingShingle Jinjuvadia, Raxitkumar, Njei, Basile M., Ditah, Ivo C., Journal of Clinical Oncology, The association between metabolic syndrome and primary liver cancer: A meta-analysis., Cancer Research, Oncology
title The association between metabolic syndrome and primary liver cancer: A meta-analysis.
title_full The association between metabolic syndrome and primary liver cancer: A meta-analysis.
title_fullStr The association between metabolic syndrome and primary liver cancer: A meta-analysis.
title_full_unstemmed The association between metabolic syndrome and primary liver cancer: A meta-analysis.
title_short The association between metabolic syndrome and primary liver cancer: A meta-analysis.
title_sort the association between metabolic syndrome and primary liver cancer: a meta-analysis.
title_unstemmed The association between metabolic syndrome and primary liver cancer: A meta-analysis.
topic Cancer Research, Oncology
url http://dx.doi.org/10.1200/jco.2012.30.4_suppl.175